Considerations for Observational Research Using Large Data Sets in Radiation Oncology by Jagsi, Reshma et al.
Considerations for Observational Research using Large
Datasets in Radiation Oncology
Dr. Reshma Jagsi, MD, DPhil [Associate Professor of Radiation Oncology] [Associate
Chair for Faculty Affairs],
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA
Dr. Justin E. Bekelman, MD [Assistant Professor],
Departments of Radiation Oncology and Medical Ethics and Health Policy, University of
Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
Dr. Aileen Chen, MD [Assistant Professor],
Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA
Dr. Ronald C. Chen, MD, MPH [Assistant Professor],
Department of Radiation Oncology, University of North Carolina at Chapel Hill School of
Medicine, Chapel Hill, NC, USA
Dr. Karen Hoffman, MD [Assistant Professor],
Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD
Anderson Cancer Center, Houston, TX, USA
Dr. Ya-Chen Tina Shih, PhD [Assistant Professor],
Department of Medicine, Section of Hospital Medicine, The University of Chicago, Chicago, IL,
USA
Dr. Benjamin D. Smith, MD [Assistant Professor], and
Department of Radiation Oncology, Division of Radiation Oncology, and Department of Health
Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr. James B. Yu, MD [Assistant Professor of Therapeutic Radiology]
Yale School of Medicine, New Haven, CT, USA
Abstract
The radiation oncology community has witnessed growing interest in observational research
conducted using large-scale data sources such as registries and claims-based datasets. With the
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growing emphasis on observational analyses in health care, the radiation oncology community
must possess a sophisticated understanding of the methodological considerations of such studies in
order to evaluate evidence appropriately to guide practice and policy. Because observational
research has unique features that distinguish it from clinical trials and other forms of traditional
radiation oncology research, the Red Journal assembled a panel of experts in health services
research to provide a concise and well-referenced review, intended to be informative for the lay
reader, as well as for scholars who wish to embark on such research without prior experience. This
review begins by discussing the types of research questions relevant to radiation oncology that
large-scale databases may help illuminate. It then describes major potential data sources for such
endeavors, including information regarding access and insights regarding the strengths and
limitations of each. Finally, it provides guidance regarding the analytic challenges that
observational studies must confront, along with discussion of the techniques that have been
developed to help minimize the impact of certain common analytical issues in observational
analysis. Features characterizing a well-designed observational study include clearly defined
research questions, careful selection of an appropriate data source, consultation with investigators
with relevant methodological expertise, inclusion of sensitivity analyses, caution not to
overinterpret small but significant differences, and recognition of limitations when trying to
evaluate causality. This review concludes that carefully designed and executed studies using
observational data that possess these qualities hold substantial promise for advancing our
understanding of many unanswered questions of importance to the field of radiation oncology.
INTRODUCTION
The radiation oncology community has witnessed growing interests in observational
research conducted using large-scale data sources such as registries and claims-based
datasets. Given the low barriers to accessing certain sources of such data and the recent
emphasis on understanding the “real-world” outcomes of medical interventions, studies
relying on registry and/or claims data have proliferated in the Red Journal and the general
oncology literature in recent years.
Although the literature of health services research contains detailed resources to guide the
design and interpretation of such studies,12345678910111213 and some reviews have
considered specific topics of interest to the radiation oncologist, 141516171819 we are aware
of no single, comprehensive overview specifically targeted towards the radiation oncologist
who seeks to conduct or interpret such studies. Because observational research has unique
features that distinguish it from clinical trials and other forms of traditional radiation
oncology research, the Red Journal assembled a panel of experts in health services research
to provide a concise and well-referenced overview, intended to be informative for the lay
reader of the Red Journal, as well as for scholars who wish to embark on such research
without prior experience.
In this manuscript, we begin by discussing the types of research questions relevant to
radiation oncology that large-scale registry data may help illuminate. We then describe
major potential data sources for such endeavors, including information regarding access and
insights regarding the strengths and limitations of each. Finally, we provide guidance
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regarding the analytic dilemmas that observational studies must confront, along with
discussion of the techniques that have been developed to help minimize the impact of certain
common challenges in observational analysis.
RESEARCH QUESTIONS
Many different kinds of studies can be performed with registry and/or claims data. These
data have two distinctive advantages over clinical trials data: 1) the large sample size of the
database and 2) the “real world” nature of the data. This section outlines several types of
studies that can be explored with such data. This is by no means an exhaustive list, and other
novel and creative uses are certainly possible.
Rare cancers and rare events
The characterization of the incidence and survival of patients diagnosed with rare cancers is
one potential project that can be performed with large observational datasets. In particular,
cancers which arise in a rare site20 or a rare histology21 benefit from the characterization of
relatively straightforward concepts such as survival and patterns of presentation that would
otherwise be difficult to obtain in single institution experiences. Large observational
databases may also be useful in studies exploring the potential role for radiotherapy in the
management of rare diseases. However, it is important to recognize that these studies are
limited by variations in the expertise of the diagnosing pathologist, as there may be
significant limitations for both sensitivity and specificity when attempting to accurately
determine a rare diagnosis. In addition, these data are useful for characterizing rare events
like radiation-induced second malignancies.22
Changes in practice patterns
As radiation oncology is a rapidly changing field, the investigation of changes in radiation
practice patterns over time is a particularly fertile area of research. For example, whether
treatment patterns have changed in response to clinical evidence,23 randomized trials,2425 or
clinical guidelines26 is important in order to identify areas where further education is
needed.
In particular for radiotherapy, investigating the dissemination of new technologies is also
important, though dependent on the ability of the data to record whether new technology has
been delivered. Dissemination of intensity modulated radiation therapy (IMRT)27 and
adoption of computed tomographic (CT) treatment planning28 for lung cancers are two
examples of areas where registry data have led to useful insights to the sociodemographic
factors associated with the diffusion of important technology. Often, studies of new
technology dissemination are limited by whether the data collected by registries or present in
administrative claims are specific enough to identify the treatment to be studied. For
example, studies of the use of accelerated partial breast irradiation using claims data have
had to focus on brachytherapy utilization because the receipt of external beam partial breast
irradiation cannot reliably be differentiated from incomplete courses of whole breast
irradiation in claims data alone.
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Prediction models and nomograms
The creation of predictive models and nomograms is an area of potential research that is also
dependent on a data source with diverse patient information. Some of the earliest pioneering
work using cancer registry data was the characterization of survival of men following
conservative management of prostate cancer, the so-called “Albertson tables.”29 This work
has subsequently been updated,30 and as the manner and stage in which patients present over
time continues to change, updating of these tables will be needed.
Nomograms predicting benefit from post lumpectomy radiotherapy for older patients with
breast cancer have been developed31 to define subpopulations of patients who would have
larger benefit from treatment.32 These types of studies are valuable and give patients more
specific insights into the outcomes from patients similar to them.
Comparative effectiveness
Perhaps the most interesting area of current research using observational data in radiation
oncology is to explore the comparative effectiveness of new technologies in the treatment of
cancer. Observational studies using registry and/or claims data are particularly important
where clinical trials are not forthcoming, will not be available during a time of rapid
technology adoption, or will not be conducted at all. Furthermore, randomized trials can
sometimes prioritize internal validity (the measurement of cause and effect with minimized
bias within the study sample) over external validity (the application of study results to
patients in the source population who are not included in the study sample). The external
validity of randomized studies may be limited if the treatment arms, outcomes, or follow up
periods tested are different or unrelated to current clinical practice33 or if the participants are
not representative of the patient population, a concern frequently voiced for elderly cancer
patients.34 Large observational studies are advantaged by their ability to draw information
from a diverse array of patients, providers, and treating facilities in real world practice.
Examples of comparative effectiveness research where clinical trials already exist include
IMRT compared to 3D conformal radiotherapy for head and neck cancers.35 As for
randomized patients, survival of patients with IMRT for head and neck cancers in
community practice has been shown equivalent to 3D conformal RT36 though continued
diligence as to complications from treatment is needed.37 Examples of comparative
effectiveness where relevant randomized trials are ongoing include the comparative
effectiveness of different types of radiotherapy for prostate cancer, including the comparison
of 3D CRT and IMRT38 and proton radiotherapy394041 and the comparison of breast
brachytherapy to standard breast radiotherapy.4243 It is notable that these examinations of
comparative effectiveness are limited by how up-to-date the data are, whether specific
treatment codes are available, and whether complications are adequately captured by
administrative claims. In particular, it is important to note that the diffusion of certain
technologies may be limited in the early years of use, in which case even the experiences in
a multi-institutional registry may reflect treatment at only one or a few select centers.
In summary, there are a wide variety of potential studies to be performed using registry or
claims data. These studies typically take advantage of the large sample size and treatment
Jagsi et al. Page 4






















diversity available in such data. These studies are helpful in delineating the treatment and
presentation of cancers both rare and common, understanding changes and variations in
treatment patterns, and particularly helpful in investigating the comparative effectiveness of
new technologies both where randomized trials have not yet been completed, or where
external validation is needed.
DATA SOURCES
Numerous potential datasets exist that are suitable for the investigation of questions relevant
to the practice of radiation oncology (Table 1). In this section, we describe several
commonly used data sources, with attention to the relative strengths and limitations of each.
The Surveillance, Epidemiology, and End Results (SEER) Data
The Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer
Institute is a collection of population-based cancer registries which began collecting data on
January 1, 1973, in Connecticut, Iowa, New Mexico, Utah, Hawaii, Detroit, and San
Francisco/Oakland.44 Over time, additional registries were added and SEER program now
includes a total of 20 registries covering approximately 28% of the US population.44 The
data collected include: demographics (race and ethnicity, age at diagnosis, month and year
of diagnosis, gender, marital status, state and county of residence at time of diagnosis),
tumor site, tumor morphology, stage at diagnosis, first course of treatment (information on
surgery and radiation but not systemic therapy), and survival (including cause of death from
the death certificate). SEER data can be obtained free-of-charge; a signed data use
agreement form is required, and data request can be found on the SEER website (http://
seer.cancer.gov/data/). The website also provides data analytic tools.
The population-based nature of SEER makes it a powerful data source to examine temporal
changes in cancer incidence, patterns of care, and survival, with results generalizable to the
US population. The limitations mainly relate to the lack of certain data elements, including:
systemic therapy, treatment after the first course, disease recurrence, comorbidities and
functional status, and health related quality of life (HRQOL). Further, recent data suggest
that SEER may underascertain post-operative radiation therapy.4546 This can lead to
spurious findings of underutilization or variation in the use of radiation therapy that are in
fact artifacts of incorrect data.47 Therefore, there has been interest in combining the detailed
pathologic information in SEER with other data, such as claims or surveys, as described in
subsequent sections.
SEER-Medicare
Data from the SEER cancer registries have been linked with Medicare administrative claims
data to provide enriched information about Medicare beneficiaries with cancer.4849 The
linked SEER-Medicare dataset contains information from the SEER registries (patient
demographics, tumor characteristics, initial treatment and vital status) as well as billing
claims for fee-for-service Medicare beneficiaries. The claims contain diagnostic and billing
codes generated for services covered by Medicare including tests, procedures, office visits,
admissions, durable medical equipment, home health, hospice care, and prescription drugs.
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The most recent linkage, performed in 2012, includes cancer diagnoses through 2009 and
Medicare claims through 2010.49 Medicare covers individuals younger than 65 if they are
disabled or have end-stage renal disease, however, most investigators use SEER-Medicare to
study individuals age 65 and older. Since Medicare insures nearly all individuals age 65 and
older, the data are fairly representative of national cancer care for older cancer patients
enrolled in fee-for-service Medicare in the United States.
The linked SEER-Medicare claims provide insight about patient medical conditions,
pretreatment evaluation, initial treatment and subsequent medical care that is not available in
SEER data alone. Medical diagnosis codes in claims generated the year prior to cancer
diagnosis are commonly used to characterize patient comorbid medical conditions.48 Claims
for imaging services can be used to evaluate assessment at diagnosis and surveillance after
treatment. For example, procedure codes have been used to study the impact of breast MRI
on type of breast cancer surgery and to evaluate the frequency of surveillance colonoscopy
in colorectal cancer survivors.5051 Claims can identify treatments not captured in SEER
including chemotherapy administration, androgen deprivation therapy administration, and
type of reconstructive surgery.525354 Although SEER collects data regarding administration
of radiation during the first course of treatment, the linked Medicare claims can identify
radiation administration not captured in SEER46 and provide additional granularity
regarding type of radiation administered.55 The linked SEER-Medicare database has been
used to compare the use and outcomes of 3D-conformal radiotherapy, IMRT, proton
radiotherapy, and stereotactic radiosurgery, which would not be possible using SEER
alone.28405657 Since multiple years of claims data are available, beneficiaries can be
followed longitudinally over time. The longitudinal nature of claims data facilitates the
study of events that occur after initial diagnosis and treatment such as procedures for post-
treatment complications, surveillance follow up evaluation, cancer treatments for recurrence,
and end-of-life care.55859 Because claims data reflect billed medical services, they are also
uniquely suited to study the cost of care.2
The linked Medicare claims provide additional information about the health, treatment, and
outcomes of cancer patients; however, research using the linked claims has distinct
limitations as well. First, it is important to remember that claims data are administrative data
not clinical data. Claims only contain services covered by and billed to the insurer. Medical
care not billed to Medicare, such as services provided to beneficiaries by the Veterans
Administration, Military Medical System, or community-sponsored screening programs are
not captured. Second, claims are generated for billing. Information needed to obtain
payment, such as the procedure performed, is of higher quality than information not required
to obtain payment, such as secondary diagnoses. Third, claims reflect care that patients
received rather than care that patients may have needed. Therefore, studies that use
administration of salvage cancer treatment as a surrogate for cancer recurrence may miss
patients whose cancer recurred but who declined salvage treatment. Fourth, there is limited
information on why a patient did or did not receive a medical service. Fifth, although post-
treatment complications can be inferred from diagnostic and billing codes, there are no
patient-reported outcomes in claims data. Sixth, data for individual claims are only available
for fee-for-service Medicare beneficiaries. Therefore, most studies using SEER-Medicare
are limited to fee-for-service beneficiaries with continuous enrollment, despite the fact that
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patients and their care may differ between the fee-for-service and managed care settings.60
Seventh, prescription drug data are available only since 2006 onwards and for those
beneficiaries with Part D Medicare coverage. Eighth, there is no follow up for cancer
recurrence from the SEER registry data. Ninth, researchers can identify receipt of tests
covered by Medicare (e.g., PSA, KRAS) but do not know the results of the tests. Finally,
Medicare claims provide information about older patients with cancer but patterns of care
and outcomes may be different for younger patients.61
Despite these limitations, SEER-Medicare data offer a unique opportunity to evaluate
medical care for older cancer patients prior to diagnosis, during initial treatment, and after
treatment, as well as the cost and quality of care. The data can be linked to other sources as
well, including the Area Resource File to study the impact of health resources on medical
care, the American Medical Association Physician Masterfile to study physician
characteristics, and the American Hospital Association Annual Survey Database to study
hospital characteristics. 3 Of note, physician characteristic linkages are imperfect, 4 and one
study identified potential misclassification in particular for radiation oncologists.62
Restricted geographic identifiers, i.e., census tract of residence, also are available for linkage
to US Census tract-level data. A random sample of Medicare beneficiaries who do not have
cancer is also available for comparative analyses.
Researchers interested in conducting studies utilizing SEER-Medicare data must obtain
approval from the National Cancer Institute for specific research questions and complete a
data use agreement (DUA). It should be noted that the DUA is strictly tied to the specific
questions approved by the NCI and researchers planning to use the same data to study
questions outside the scope of the DUA have to submit a new proposal to seek approval for
a new DUA. In addition, manuscripts using SEER-Medicare data have to be approved by the
NCI prior to submitting to a journal. The cost of the data depends on the number of files
requested, and a separate level of approval is necessary to obtain access to data like
restricted geographic identifiers. Separate files contain data on hospital inpatient services,
hospital outpatient services, physician payments, home health, hospice, skilled nursing
facilities and outpatient prescription drugs. The data files are large and complex and require
computing power and advanced data management skills to create an analytic dataset. Given
the complexities of the data, it is helpful to work with someone who has experience with the
data when first using SEER-Medicare data. Of note, new measures are added to SEER-
Medicare over time (e.g., AJCC M1 substaging for site of metastasis, HER2 status in breast
cancer) to permit more granular sample definition; typically, the year in which the measure
is first made available is excluded when conducting analyses using the measure. The NCI
periodically offers videocasts of training workshops that may be particularly useful
resources for beginners interested in working with this data source.63
Claims-based datasets
Medical claims data that have not been linked to cancer registry information encompass a
broader population. In contrast to the linked SEER-Medicare database which is limited to
beneficiaries diagnosed in a SEER registry (approximately 26% of the population), the
Chronic Conditions Warehouse is a nationally comprehensive database that contains 100%
Jagsi et al. Page 7






















of all Medicare fee-for service claims for all beneficiaries. Claims for younger patients can
be obtained from several private sources, such as the MarketScan database which contains
inpatient, outpatient and pharmaceutical claims from more than 100 payors in all 50 states.60
Other proprietary commercial claims data include IMS LifeLink data, United Healthcare
claims data, Humana claims data, among others. Although the commercial claims data
provide information on a younger population, only privately insured individuals are included
and long-term follow up can be limited due to frequent changes in insurance plans in the
younger population.
Claims-based datasets are subject to the limitations of SEER-Medicare data as outlined
above. Additionally, claims-based algorithms must be applied to these datasets to identify
incident cancer cases.64 While some such algorithms have been validated, they inevitably
have certain limitations and thus will omit some patients with the cancer to be studied and
also include certain patients without a true diagnosis of cancer or mistaken prevalent cases
as incident cases.65 Accordingly, great care should be applied when posing study questions
with claims-only data to ensure that findings will not be sensitive to this inherent limitation.
Additionally, there is no information about cancer stage or cancer histology. Algorithms to
derive stage from claims data have been developed for breast cancer, but are limited in their
predictive power.66 In certain cases, biologic information from the tumor may be derived,
for example if a prescription for endocrine therapy is identified, it may be reasonable to infer
that the patient’s breast cancer was estrogen receptor positive. Another limitation of some
claims-based datasets is that they may not include race/ethnicity data as a matter of company
policy, and this precludes those data from use in studies of race disparities.
Certain limitations of claims-based algorithms can pose particular challenges for those
investigating issues in radiation oncology. For example, algorithms to identify delivery of
palliative radiation to the bone have also been developed using claims but have yet to be
validated.676869 Studies of skeletal-related events using claims data are limited by absence
of clinically confirmed diagnosis of bone metastasis, and prior literature documents
concerns with misclassification when using billing codes to identify cancer recurrence or
metastasis. 7071 In addition, although claims data do allow for the identification of certain
events relative to diagnosis or another index date (such as timing of face-to-face contact
with a radiation oncologist, timing of receipt of radiation therapy), other measures that may
be of interest to radiation oncologists cannot be determined, including site of radiation
delivery (e.g., to the bone or organ) and length of radiation therapy (e.g., 4 week course or 6
week course—although the total number of treatment fractions billed can be useful in this
regard). Researchers using claims data will often create episodes of care in order to properly
characterize utilization and costs associated with treatment for a given event or purpose. For
example, a patient experiencing a fracture may generate claims related to the initial fracture
event over the course of several weeks or months as they receive treatment and return to
visit their physicians for follow-up care. While claims data present opportunities to
investigate real-world utilization patterns, it is not often straightforward to isolate utilization
and costs associated with specific events or conditions using claims data.
Medicare claims data can be obtained from Centers for Medicare and Medicaid Services
(CMS) through the Research Data Assistance Center (www.resdac.org) and require an
Jagsi et al. Page 8






















extensive data security plan and approval of the CMS Privacy Board. Commercial claims
data can be obtained from their respective data vendor (e.g., Truven Health Analytics
(www.truvenhealth.com) for MarketScan database) and licensing fees typically differ
between researchers in academic and non-academic settings.
Survey Datasets
Some researchers have sought to enhance population-based sources of data with surveys that
elicit information from patients themselves. Strengths of survey data include the ability to
collect information reflecting patients’ own perceptions and experiences with care, as well
as data relating to domains such as quality of life that are best evaluated using patient-
reported outcomes measures. Growing interest in patient-reported outcomes727374 has led
many registries to begin exploring ways in which to incorporate patient-reported data in
their datasets. Limitations relate to the selection bias that can be introduced by non-response,
and studies relying on survey datasets with low response rates should be viewed with
considerable caution.75
The SEER-MHOS (Medical Health Outcomes Survey) linked database results from a
collaboration between the National Cancer Institute and the Centers for Medicare &
Medicaid Services (CMS).7677 MHOS is a survey administered to a sample of Medicare
managed care beneficiaries: 1,200 beneficiaries are randomly selected per managed care
plan each year (1,000 per year from 1998-2006). The latest dataset available at the time of
press includes cases diagnosed through 2009, with follow-up through 2011. For each
selected beneficiary, a baseline survey is mailed and followed up with a phone call if no
response was received; a follow-up survey two years later is administered the same way.
Data collected include participant-reported demographics (age, gender, race and ethnicity,
marital status, household income, education, smoking status), comorbid conditions,
functional status and general HRQOL (assessed using the Short-Form 36 in years
1998-2005, and Veterans RAND 12-item Health Survey from 2006 and later). To obtain
linked SEER-MHOS data, a data request and proposal need to be submitted for review
(http://appliedresearch.cancer.gov/surveys/seer-mhos/obtain/req.docs.html). If approved,
there is a cost to obtain the dataset and other procedures that must be followed.
SEER-MHOS is a unique, population-based data source to examine HRQOL of cancer
patients, and also includes a number of self-reported comorbid conditions and functional
status measures – thus, this linked dataset improves on some important limitations of the
SEER alone. However, SEER-MHOS contains only patients 65 years or older, and overall
has a relatively limited sample size. Because MHOS was not designed specifically to study
HRQOL in cancer patients, sampled participants may have no history of cancer; in
participants with cancer, survey administration is often not coincident with the time of
cancer diagnosis or treatment. Further, no disease-specific HRQOL measures are used and
long-term longitudinal assessment of HRQOL changes is not possible. In addition, data
quality for longitudinal assessment of HRQOL changes is poor because a follow-up survey
is administered to the same cohort two years after the baseline survey and the follow-up
survey is limited to beneficiaries who are still enrolled in Medicare managed care plans.
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Other sources of SEER-data linked to surveys also exist, and access to these may be
available through request to the investigators who have developed these initiatives. For
example, the Cancer Surveillance Outcomes Research Team (CanSORT) is a collaborative
group funded by the National Cancer Institute to survey cohorts of newly diagnosed breast
cancer patients in selected SEER regions in order to evaluate their decision-making
experiences, satisfaction, and quality of life.78 Detailed patient data on treatments received
are linked to SEER data on pathologic and clinical disease characteristics and have been
used to illuminate patterns of radiation therapy receipt as well as potential causes for
variation in care.79
The Cancer Care Outcomes Research and Surveillance Consortium (CanCORS), funded by
the National Cancer Institute in collaboration with the Department of Veterans Affairs,
represents another valuable source of patient survey data. It focuses on newly diagnosed
patients with colorectal or lung cancer from geographically diverse populations and health
care delivery systems nationwide and includes data from medical records, as well as
physician and patient surveys.80 CanCORS data have been used for a number of purposes,
including comparison of practice patterns for palliative radiation to clinical evidence and
evaluation of metastatic cancer patients’ perceptions of the intent of radiation therapy.818283
National Cancer Data Base (NCDB)
The National Cancer Data Base is a joint program of the Commission on Cancer (CoC) of
the American College of Surgeons and the American Cancer Society, and collects data from
over 1,400 CoC-accredited cancer hospitals throughout the US. The NCDB contains data on
approximately 70% of incident US cancer patients.84 The NCDB was started in 1989, and
by 1996, reporting of cancer cases was required of all CoC-accredited hospitals, which
include teaching, community, and Veterans Health Administration hospitals. At each
hospital, certified tumor registrars abstract data from patient medical records, and registrars
are required to obtain and submit patient treatment and follow-up data even if part of the
care is received at another (e.g. non-CoC-accredited) hospital. Annually, registrars upload
data to the NCDB on incident cancer cases as well as follow-up information on existing
patients. Data contained in the NCDB include: demographics (age, gender, race, marital
status, medical insurance), comorbidity status, stage, treatments received, recurrence and
survival.
NCDB data can be obtained by investigators from CoC-accredited programs through an
application process (see http://www.facs.org/cancer/ncdb/participantuserfiles.html). If
approved, data are provided free of charge.
The NCDB is a powerful source of data for research given its large size, and inclusion of
information on use of systemic therapy, comorbidities, and recurrence. However, an
important limitation is that the NCDB is not population-based thus limiting generalizability
– data are entered from accredited hospitals, and this selection may bias findings toward
higher quality care and patient outcomes.85 Specifically, although cancer diagnoses at
hospitals approved by the Commission on Cancer (CoC) constitute 70% of all new cancer
diagnoses in the U.S., CoC-approved hospitals are larger, more frequently situated in urban
locations, and have more cancer-related services available to patients. Further, patients who
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are diagnosed and receive all of their cancer care in the outpatient setting without entering a
CoC-accredited hospital are not included in the NCDB.
Centers of Excellence
Many large institutions maintain their own hospital registries, and some have joined together
in collaborative registries, such as the one maintained by the National Comprehensive
Cancer Network (NCCN).86 Registries from centers of excellence are often restricted to
investigators with an affiliation with a member site. The strengths of such datasets include
the potential for access to highly detailed clinical information that may even extend to the
level of dosimetric or other potentially relevant granular data. For example, the NCCN
database contains more than 300 data elements that track the continuum of care
longitudinally, including information on all clinical interventions. Their primary limitation is
their failure to include a population-based sample. Selection effects can be highly
problematic; estimates based on registries that include primarily centers of excellence are
vulnerable towards significant bias.
Radiation oncology-specific registries
In recent years, radiation oncologists have begun to assemble registries that include both
academic and community sites to gather detailed radiation treatment planning information
that may be particularly relevant for the investigation of the comparative effectiveness of
radiation therapy and that other registries have traditionally lacked. ASTRO and the
Radiation Oncology Institute are embarking on the nascent National Radiation Oncology
Registry (NROR), which aims to monitor and improve the quality of care for patients treated
with radiation.8788 In the state of Michigan, Blue Cross Blue Shield has funded a
Collaborative Quality Initiative known as the Michigan Radiation Oncology Quality
Consortium (MROQC). MROQC collects detailed dosimetric, clinical, and patient-reported
outcomes data from multiple academic and community sites across the state, on all patients
treated with adjuvant whole breast irradiation after lumpectomy and radiation therapy for
lung cancer with curative intent.89
As these endeavors grow and mature, they will serve as unique sources of information for
those wishing to compare different forms of radiation treatment. Their primary limitation is
the especially resource-intensive nature of collecting detailed dosimetric information
relating to radiation treatment plans and the fact that they are still works in progress.
Canadian, European, and Asian Oncology Databases
Although the preceding sections have focused on data sources that have been assembled in
the United States, many countries outside the United States have robust registries or
administrative claims data at the provincial or even national level, and these may be
promising sources for the investigation of key research questions. A listing of some of these
non-US oncology databases can be found at http://www.ispor.org/OncologyORResources/
SearchOcologyResources.aspx.
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In oncology, we are often interested in comparing the effect of different interventions or
treatments. Randomized studies are the gold standard for determining whether one treatment
is superior to another. However, for practical or ethical reasons, randomized studies are not
always possible. In these situations, well-conducted observational studies can provide useful
information to influence decision-making. One common challenge in analyzing
observational data is that treatments are not randomly assigned. Therefore, it is possible that
characteristics of patients, providers, or healthcare systems, both observed and unobserved,
can influence not only treatment assignment, but also outcomes. For example, sicker patients
might be less likely to receive aggressive treatment, and they may also be more likely to
have a poor outcome, regardless of the treatment received. Analyses not accounting for such
favorable selection into the more aggressive treatment will thus overestimate the benefit of
the treatment. For example, one study 90of patients with prostate and colon cancer in the
SEER-Medicare database found that analysis of these observational data produced
improbable results. They found that men with locally advanced prostate cancer who
underwent androgen deprivation had higher prostate cancer mortality (hazard ratio, 1.5; 95%
confidence interval, 1.29-1.92). Clinical trials have provided strong evidence that androgen
deprivation improves cancer mortality, so this finding almost certainly reflects selection
bias.
Traditional regression-based methods to address confounding
To deal with the issue of confounding due to nonrandom treatment assignment, several
statistical and econometric techniques are commonly employed, including multivariable
regression analyses that attempt to control for potential confounders in observational studies.
Researchers often start with a series of descriptive bivariate analyses to explore the
unadjusted correlation between each explanatory variable and the outcomes of interest, then
follow with multivariable models to include the treatment variable (quantified as a binary
variable with 1 indicating the treatment received by patients in the case group and 0
otherwise) plus other potential confounders in the same model. Variations on multivariable
regression models, including stepwise selection algorithms and survival models for time-
dependent effects, are also frequently used. In theory, if all important confounders were
observed and controlled for, multiple regression techniques could produce similar results
from an observational study that would be observed in a randomized study.
Propensity score models
Standard multiple regression techniques are limited, however, by specific assumptions about
the relationship between the covariates and outcome and also by the fact that not all
confounders may be observable. In these situations, propensity score models and
instrumental variable analysis can play an important role in improving the accuracy of
statistical inferences.
Propensity score methods assign a probability of receiving the new treatment or the
intervention received by patients in the case group to each individual based on observed
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covariates, and can be implemented in several ways, including covariate adjustment and
matching.9192 In covariate adjustment, propensity scores (predicted from a logistic
regression) are simply entered in the regression model as an additional explanatory variable
for the outcome. In propensity matching, strata are created by grouping individuals by
propensity scores and calculating the treatment effect within those strata. Unlike standard
multiple regression models, propensity scores do not assume a specific relationship between
the covariates and outcome (e.g. linear or log linear), but rather assign a probability or
“propensity” for each individual to be assigned to a treatment group, based on observed
characteristics. Therefore, like multiple regression models, propensity score methods are
limited by the assumption that all factors affecting treatment assignment are accounted for
by observable covariates. Furthermore, propensity score matched models do not include
patients who remain unmatched, and therefore require large datasets with significant overlap
in patient characteristics. Such approaches have been used previously in numerous studies of
topics relevant to radiation oncology.284057
Of note, in the study described above, in which locally advanced prostate cancer patients
who received androgen deprivation fared worse, controlling for comorbidity, extent of
disease, and other characteristics by multivariate analyses or by propensity analyses had
remarkably small impact on the improbable results.90 Thus, caution must be employed when
attempting to use observational data to evaluate the impact of treatments on patient
outcomes, even when techniques to address measured confounding factors have been
applied. Other methods that arise from the causal inference literature, including instrumental
variable analysis, inverse probability treatment weights,93 and marginal structural models94
have also been proposed for observational comparative effectiveness research.
Instrumental variable analysis
Instrumental variable analysis is an econometric technique to remove the effects of hidden
bias95 and, unlike propensity scores, does not assume that all potential confounders are
observed. The key assumption is that the instrumental variable does not affect the outcome
directly, except through treatment assignment. Therefore, a good instrumental variable
should be strongly correlated with treatment assignment (referred to as “instrument
relevancy” in the econometric literature), yet lacking an independent effect on the outcome
(referred to as “instrument exogeneity”). If an instrument is weak, (i.e. the proportion of
treatment assignments in the instrument groups are about the same) then the estimate of
treatment effect becomes unstable.96 In practice, it is often very difficult to identify a good
instrumental variable for a particular treatment and outcome, which can limit the use of this
technique. In certain cases, use of geographic variables, such as local area treatment rate97
or differential distance to a treating facility,4398have been appropriate instruments. Upon
identification of a set of candidate instrumental variables, it is important to check the
validity of these instruments. Once a set of valid instruments are identified, it is also
important to verify whether the treatment variable is indeed “endogenous” (i.e., the
treatment variable is correlated with the error term). If treatment variable is in fact
exogenous, the use of instrumental variable method is unnecessary and can lead to
efficiency loss.
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Instrumental variable approaches do not estimate the average effect of treatment in a
population, but rather the average effect for patients whose treatment was induced by the
instrument. The treatment effect produced by instrumental variable analysis applies to what
has been called the “marginal” or “complying” patient population, defined as patients whose
treatment status depends strongly on the instrument. Research should describe which
patients comprise the marginal patient population to inform the generalizability of findings
from instrumental variable methods.99 Several examples of recent articles in radiation
oncology using these techniques exist.409798100101102
Handling Missing Data
Missing data is a common problem in randomized and non-randomized studies. Data can be
missing because patients are lost to follow-up, centers are unable to collect certain variables
for all patients, or myriad other reasons. The main concern is whether missing data could
bias study results; this concern is heightened in studies of comparative effectiveness when
the level of missing data is different between study groups. Therefore, all studies must
address how missing data were handled in analyses.
Many approaches exist to handle missing data; we mention three here. The first approach
involves omitting everyone without complete data, and is known as complete case analysis.
However, if a large proportion of patients have missing data, their exclusion could result in a
substantial loss of statistical power and biased results, especially if the discarded cases differ
systematically from those retained. A second approach involves entering missing data into
regression models as dummy variables. The downsides of this approach are similar to
complete case analysis and, when levels of missing data are greater than 3 to 5% (as a
general rule of thumb), this approach has also been shown to yield biased results.103
Multiple imputation, the third approach, is commonly available in statistical packages and is
accepted as the most valid method for handling missing data. Multiple imputation can be
thought of as a method to represent the uncertainty of missing data in regression models, and
involves the creation and combination of multiple datasets produced through the imputation
process. As with any statistical approach, the validity of the results of multiple imputation
depends on careful and appropriate modeling.
In summary, we recommend the following best practices for handling missing data in
observational research.104 First, reports should describe the number of patients excluded for
missing data and the number and proportion of missing values for each variable of interest.
Second, reports should examine differences between patients with complete or incomplete
data across exposure and outcome variables. Third, reports should describe the methods
used to handle missing data and the assumption or rationale for the approach. Lastly, reports
should discuss whether and how missing data might bias study results, even in the context of
valid approaches used to handle missing data (particularly if missingness may differ
between study groups in comparative analyses). Several articles can be referred to for
further background.105106107
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Analysis of Medical Costs Data
Studies examining the economic impact of an illness or a new treatment often are interested
in estimating medical costs associated with the illness or treatment. When preparing the data
for cost analysis, it is important to normalize the cost data to the same year of currency (e.g.,
in 2013 US dollars) by applying the appropriate inflation adjustment index, such as the use
of Medicare Prospective Payment System adjuster and the Medicare Economic Index for US
costs data extracted from Medicare Part A and B claims, respectively. It should also be
noted that the type of cost information available varies by datasets. Some provide
information on payments as well as charges (e.g., Medicare claims), while other record only
payment (e.g., MarketScan) or charges (e.g., Nationwide Inpatient Sample or NIS). When
both charges and payments are reported in the data, it is recommended that researchers use
the payment variable for medical costs since charges are often highly inflated from the
actual costs. If only charge information is provided, cost-to-charge ratio should be applied to
obtain better cost measure.
Medical cost data tend to be highly skewed, with a small proportion of very ill patients
incurring excessively high costs; therefore, when comparing costs between two
interventions, the commonly used t-test for continuous variables is often inappropriate
because cost variable is unlikely to be normally distributed. The recommended approach to
compare mean medical costs when cost data are highly skewed is the nonparametric
bootstrap method suggested by Barber and Thompson.108 The violation of normality
assumption also complicates the multivariable regression models since estimates based on
the standard ordinary least squares (OLS) technique can be severely biased if the dependent
variable is highly skewed. Historically, researchers applied the log-transformed model to
deal with this issue. However, more recent econometric literature has pointed out that
despite its ease of implementation, the log-transformed model must take into consideration
of the role of heteroscedasticity when retransforming the estimate from log(cost) back to
cost.109 Generalized linear models (GLM) offer a nice alternative to the log-transformed
model and can avoid the retransformation issue. The challenge for the GLM model is that
one must specify a mean and variance function and the best model to use depends on the
characteristics of the data.110 More advanced methods, such as the extended estimating
equations (EEE) approach,111 have been developed to relax the requirement of GLM
models. In general, applied econometricians agree that no one model universally dominates
the others under all circumstances.111112 Given these complexities, it is highly advisable that
studies of medical costs include individuals with relevant econometric expertise among the
investigator team. Furthermore, medical costs data can be censored due to reasons such as
loss of follow-up (e.g., switch from a fee-for-service plan to a HMO) or end of data
collection period, resulting in partial observation of costs for patients whose data are
censored. Methods such as the inverse probability weighted least squares method,113 Lin’s
regression method,114115 and Carides’ two-stage method 116have been proposed to address
the censoring issue in medical costs data. A comprehensive review can be found in
Huang.117
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Finally, no discussion of the analytic challenges of observational research using large
datasets would be complete without mention of the risk of spurious findings when many
exploratory analyses are performed without pre-specification or theoretical justification. A
statistically significant p value does not guarantee that the relationship observed is not due to
chance, and the risk of finding chance associations increases when there is a “greater
number and lesser preselection of tested relationships.”118 It is also important to note that
the large size of observational datasets allows for the detection of relatively small
differences; statistical significance does not imply clinical significance, and these issues
must be addressed in the interpretation of any large-scale study, including observational
studies.
CONCLUSIONS
In summary, carefully designed and executed studies using observational data hold
substantial promise for advancing our understanding of many unanswered questions of
importance to the field of radiation oncology. Several common features characterize a well-
designed observational study. These include clearly defined research questions, careful
selection of an appropriate data source, collaboration or at least consultation with
investigators with relevant methodological expertise, inclusion of sensitivity analyses,
caution not to overinterpret small but statistically significant differences as clinically
meaningful differences, and recognition of limitations when trying to evaluate causality.
Experts have published guidelines for the conduct of comparative effectiveness research,
and radiation oncologists who seek to use registry and/or claims data for such studies should
consider their advice. For example, Table 2 reproduces a checklist for study design of an
observational comparative effectiveness research protocol from the Agency for Healthcare
Research and Quality.1 Other checklists are also available and may prove useful in
evaluating the rigor of a study’s approach.678119120121 For those seeking to evaluate the
strengths and limitations of the increasing volume of observational research in radiation
oncology, we hope that the information in this manuscript and the references provided will
prove useful and instructive.
Understanding these issues is critical because ongoing developments in the social and policy
environment are likely to lead to new opportunities and interest in observational research in
radiation oncology in the coming years. For example, the creation of health information
exchanges (secure repositories of patient health records) could support the development of a
true “learning healthcare system”122123124 in oncology care. The introduction of new
automated techniques for data extraction from medical records is likely also to introduce
new challenges and the need for ongoing evaluation of data quality and limitations. Other
changes, such as modifications of payment structures, will create opportunities for
leveraging the methods of observational research to the evaluate impact of policy changes
on outcomes. With the growing emphasis on observational analyses in health care, a
sophisticated understanding of the issues discussed herein are of critical importance to the
radiation oncology community if we are to evaluate evidence appropriately to guide practice
and policy.
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Table 1
Data Sources*
Data Source Strengths Weaknesses
Surveillance Epidemiology
and End Results (SEER)
Large, NCI-funded;
population-based; regional
cancer registries that cover
26% of US population
(reasonably representative,
though more urban, racial
differences)
Limited information about key









failure to capture all morbidity
Medicare Claims represent entire
population of Medicare
beneficiaries rather than
subset included in SEER
Generalizability (age), lack of
information on pathology and
staging, misclassification,
failure to capture all morbidity
Private Insurer Claims
Databases (e.g. Marketscan)
Includes claims data on
younger patients than
Medicare
Costly, selection of only
privately insured patients
Survey Datasets Detailed measures; some have
population-based target
population
Costly to fund, some selection
bias due to non-response
National Cancer Database
(NCDB)
Large, joint project of
ACS/ACoS, captures 70% of
all cancers diagnosed in US
Generalizability (CoC
accredited centers)














Very detailed dosimetric and
other data
Costly to establish, still in
developmemnt
*
Table includes only those sources commonly used to study U.S. patients. Additional valuable sources exist in other countries, including robust
nationwide, population-based registries.
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Table 2
Checklist: Guidance and key considerations for study design for an observational CER protocol*
Guidance Key Considerations Check
Provide a rationale for study
design choice and describe key
design features.
- Cohort study proposals should clearly define cohort entry date (baseline date),
employ a new user design (or provide rationale for including prevalent users), and
include plans for reporting losses to followup.
- Case-control study proposals should clearly describe the control sampling method,
employ a new user design (or provide a rationale for assessing confounders at index
date), and assess potential for recall bias (if applicable).
- Case-cohort study proposals should include how the sampling scheme will be
accounted for during analysis.
- Case-crossover study proposals should discuss the potential for confounding by time-
varying factors and clearly state how the resulting effect estimate can be interpreted.
- Case-time controlled study proposals should clearly weigh the pros and cons of
accounting for calendar trends in the prevalence of exposure.
□
Define start of followup
(baseline).
- The time point for start of followup should be clearly defined and meaningful,
ideally anchored to the time of a medical intervention (e.g., initiation of drug use).
- If alternative approaches are proposed, the rationale should be provided and
implications discussed.
□
Define inclusion and exclusion
criteria at start of followup.
(baseline).
- Exclusion and inclusion criteria should be defined at the start of followup (baseline)
and should be based solely on information available at this point in time (i.e.,
ignoring potentially known events after baseline).




of interest at start of followup. □
Define outcome(s) of interest. - Information should be provided on measures of accuracy if possible.
□
Define potential confounders. - Potential confounders known to be associated with treatment and outcome should be
prespecified when possible.
- Confounders should be assessed prior to exposure or treatment initiation to ensure
they are not affected by the exposure.
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